At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 417 enrolled
Drug / intervention
GK530G +2 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Multicenter, Randomized, Double-blinded, Active-controlled Parallel Group Efficacy and Safety Study of GK530G Versus CD0271 0.1% Gel and CD1579 2.5% Gel in the Treatment of Acne Vulgaris.
In Brief
A Phase 3 clinical trial evaluating GK530G, CD0271, and 1 other intervention for Acne Vulgaris. Completed, enrolled 417 participants across 13 sites.
Detailed Summary
This study is to demonstrate the superiority in efficacy of the GK530G (fixed combination of CD0271 0.1% and CD1579 2.5%) versus each of the monads (CD0271 0.1% and CD1579 2.5%) in the treatment of acne vulgaris for up to 12 weeks, in the Japanese patients.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAcne Vulgaris
CountriesJapan
Collaborators--
Timeline
Phase 3CompletedFinished
2014201520162017201820192020202120222023202420252026
First PostedFeb 2014
Enrollment StartMar 2014
Primary CompletionOct 2014
TodayJul 2026
First PostedFeb 27, 2014
Enrollment StartMar 1, 2014
Primary CompletionOct 1, 2014
TodayJul 2, 2026
Enrollment to primary: 7 monthsPosted 12.3 years ago
Interventions
GK530Gdrug
CD0271drug
CD1579drug